[UNITAID] Geneva -- Ahead of World AIDS Day, Unitaid is announcing a US$22 million investment to accelerate the introduction and access to lenacapavir, a revolutionary long-acting HIV prevention option. Two injections of lenacapavir per year, under the skin, provide effective protection against HIV. Unitaid's US$22 million investment builds on our ongoing efforts to expand supply and demand for long-acting pre-exposure prophylaxis (PrEP) products used to prevent HIV infection, ensuring this transformative innovation reaches